Treatment of Gout Flare with Significant Leukocytosis and Elevated CRP

First-Line Treatment Options

The American College of Rheumatology recommends oral corticosteroids (prednisone/prednisolone) at 30-35 mg/day for 3-5 days as first-line therapy for gout flares with significant inflammatory markers 1, 2
Specific prednisone dosing options include 0.5 mg/kg per day for 5-10 days at full dose then stop, as recommended by the American College of Rheumatology 2
Intra-articular corticosteroid injection is an excellent option if only 1-2 joints are affected, according to the American College of Rheumatology 1, 2
For patients unable to take oral medications, parenteral glucocorticoids (intramuscular or intravenous) are strongly recommended by the American College of Rheumatology 1, 2

Corticosteroids are particularly effective for gout flares with significant systemic inflammation (leukocytosis and elevated CRP) due to their potent anti-inflammatory effects, as stated by the American College of Rheumatology 1, 2
They are generally safer than NSAIDs with fewer adverse effects in the setting of acute inflammation, according to the American College of Rheumatology 2
Corticosteroids are preferred over colchicine or NSAIDs in patients with severe renal impairment, which may be a concern with significant systemic inflammation, as recommended by the European League Against Rheumatism 3, 2

NSAIDs at full FDA-approved doses can be considered if there are no contraindications, according to the American College of Rheumatology 1, 2
Low-dose colchicine (1.2 mg initially followed by 0.6 mg one hour later) is an option if started within 12-24 hours of symptom onset, as recommended by the American College of Rheumatology 1

Topical ice can be used as an adjuvant treatment for additional pain relief, according to the American College of Rheumatology 1, 2
For severe gout attacks with multiple joint involvement, combination therapy may be appropriate, including oral corticosteroids plus colchicine, as recommended by the American College of Rheumatology 2

Significant leukocytosis and elevated CRP indicate severe inflammation that requires prompt and aggressive treatment, according to the American College of Rheumatology 1
Treatment should continue until the gouty attack has completely resolved, as recommended by the American College of Rheumatology 2
If standard first-line therapies are ineffective, poorly tolerated, or contraindicated, IL-1 inhibitors may be considered, according to the European League Against Rheumatism 1, 3

Once the acute flare resolves, initiate urate-lowering therapy (ULT) with allopurinol as the preferred first-line agent, as recommended by the American College of Rheumatology 4, 5
Start allopurinol at a low dose (≤100 mg/day, lower in patients with CKD) with subsequent dose titration, according to the American College of Rheumatology 4, 6
Target serum uric acid level should be maintained below 6 mg/dL, or below 5 mg/dL for patients with severe gout, as recommended by the European League Against Rheumatism 5

Delaying treatment initiation significantly reduces effectiveness; acute gout should be treated as soon as possible, according to the American College of Rheumatology 2
Failing to rule out infection in patients with significant leukocytosis and elevated CRP, as recommended by the European League Against Rheumatism 3
Discontinuing urate-lowering therapy during acute flares - it is now recommended to continue ULT with appropriate anti-inflammatory coverage, according to the European League Against Rheumatism 5, 2
Inadequate duration of anti-inflammatory prophylaxis when initiating ULT (should be 3-6 months), as recommended by the American College of Rheumatology 4, 6